Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Teva
McKinsey
McKesson
Queensland Health
Moodys
Covington
US Department of Justice
Colorcon
Federal Trade Commission

Generated: July 21, 2018

DrugPatentWatch Database Preview

COSMEGEN Drug Profile

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

Which patents cover Cosmegen, and what generic alternatives are available?

Cosmegen is a drug marketed by Recordati Rare and is included in one NDA.

The generic ingredient in COSMEGEN is dactinomycin. There are three drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the dactinomycin profile page.
Drug patent expirations by year for COSMEGEN
Pharmacology for COSMEGEN
Synonyms for COSMEGEN
050A760
1-N,9-N-bis[(6S,9R,10S,13R,18aS)-2,5,9-trimethyl-1,4,7,11,14-pentaoxo-6,13-bis(propan-2-yl)-hexadecahydro-1H-pyrrolo[2,1-i]1-oxa-4,7,10,13-tetraazacyclohexadecan-10-yl]-2-amino-4,6-dimethyl-3-oxo-3H-phenoxazine-1,9-dicarboxam
15160-EP2272827A1
15160-EP2275420A1
15160-EP2280012A2
15160-EP2281815A1
15160-EP2289892A1
15160-EP2292615A1
15160-EP2295055A2
15160-EP2295416A2
15160-EP2295426A1
15160-EP2295427A1
15160-EP2298748A2
15160-EP2298764A1
15160-EP2298765A1
15160-EP2301928A1
15160-EP2301933A1
15160-EP2305640A2
15160-EP2305642A2
15160-EP2305671A1
15160-EP2308833A2
15160-EP2311453A1
15160-EP2311808A1
15160-EP2311827A1
15160-EP2311829A1
15160-EP2311842A2
15160-EP2316832A1
15160-EP2316833A1
1CC1JFE158
2-Amino- 4,6-dimethyl- 3-oxo- 3H-phenoxazine- 1,9-dicarboxylic acid bis- [(5,12-diisopropyl- 9,13,16-trimethyl- 4,7,11,14,17-pentaoxo- hexadecahydro- 10-oxa- 3a,6,13,16-tetraaza- cyclopentacyclohexadecen- 8-yl)- amide]
2-amino-4,6-dimethyl-3-oxo-1-N,9-N-bis-[(18aS)-10c,14,17-trimethyl-5,8,12,15,18-pentaoxo-6c,13t-di(propan-2-yl)-18ar-hexadecahydro-1H-pyrrolo[2,1-i][1,4,7,10,13]oxatetraazacyclohexadecin-9c-yl]-3H-phenoxazine-1,9-dicarboxamid
2-amino-4,6-dimethyl-3-oxo-1-N,9-N-bis[(3R,6S,7R,10S,16S)-7,11,14-trimethyl-2,5,9,12,15-pentaoxo-3,10-di(propan-2-yl)-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]phenoxazine-1,9-dicarboxamide
2-amino-4,6-dimethyl-3-oxo-N,N'-bis[(6S,9R,10S,13R,18aS)-2,5,9-trimethyl-6,13-bis(1-methylethyl)-1,4,7,11,14-pentaoxohexadecahydro-1H-pyrrolo[2,1-i][1,4,7,10,13]oxatetraazacyclohexadecin-10-yl]-3H-phenoxazine-1,9-dicarboxamid
2-amino-4,6-dimethyl-3-oxo-N1,N9-bis[(3R,6S,7R,10S,16S)-7,11,14-trimethyl-2,5,9,12,15-pentaoxo-3,10-di(propan-2-yl)-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]phenoxazine-1,9-dicarboxamide
2-amino-N,N'-bis(hexadecahydro-2,5,9-trimethyl-6,13-bis(1-methylethyl)-1,4,7,11,14-pentaoxo-1H-pyrrolo(2,1-i)(1,4,7,10,13)oxatetra-azacyclohexadecin-10-yl)-4,6-dimethyl-3-oxo-3H-phenoxazine-1,9-dicarboxamide
2-amino-N,N''-bis[(3R,6S,7R,10S,16S)-3,10-diisopropyl-2,5,9,12,15-pentaketo-7,11,14-trimethyl-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]-3-keto-4,6-dimethyl-phenoxazine-1,9-dicarboxamide
2-amino-N,N''''-bis[(3R,6S,7R,10S,16S)-3,10-diisopropyl-2,5,9,12,15-pentaketo-7,11,14-trimethyl-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]-3-keto-4,6-dimethyl-phenoxazine-1,9-dicarboxamide
2-amino-N,N''''''''-bis[(3R,6S,7R,10S,16S)-3,10-diisopropyl-2,5,9,12,15-pentaketo-7,11,14-trimethyl-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]-3-keto-4,6-dimethyl-phenoxazine-1,9-dicarboxamide
2-amino-N1,N9-bis[(3R,6S,7R,10S,16S)-3,10-diisopropyl-7,11,14-trimethyl-2,5,9,12,15-pentaoxo-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]-4,6-dimethyl-3-oxo-phenoxazine-1,9-dicarboxamide
2-azanyl-4,6-dimethyl-3-oxidanylidene-N1,N9-bis[(3R,6S,7R,10S,16S)-7,11,14-trimethyl-2,5,9,12,15-pentakis(oxidanylidene)-3,10-di(propan-2-yl)-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]phenoxazine-1,9-dicarboxamide
3H-Phenoxazine-1,9-dicarboxamide, 2-amino-N,N'-bis(hexadecahydro-2,5,9-trimethyl-6,13-bis(1-methylethyl)-1,4,7,11,14-pentaoxo-1H-pyrrolo(2,1-i)(1,4,7,10,13)oxatetra-azacyclohexadecin-10-yl)-4,6-dimethyl-3-oxo-
50-76-0
AB00514445-05
AC1L9W52
ACT [antibiotic]
Actactinomycin A IV
ActD
Actinomycin
Actinomycin 7
Actinomycin C1
actinomycin D
Actinomycin D, for fluorescence, >=90% (HPLC), from Streptomyces sp.
Actinomycin D, from Streptomyces sp., >=95% (HPLC)
Actinomycin D, from Streptomyces sp., ~98% (HPLC)
Actinomycin D, from Streptomyces sp., suitable for cell culture, >=95%
Actinomycin IV
AI3-26374
AKOS030228553
BDBM43866
BDBM50089528
BRD-K70578146-001-01-8
CAS-50-76-0
CCG-101134
CHEBI:27666
CHEMBL1554
CHEMBL3792960
cid_457193
Cosmegen Lyovac
CPD000469227
CTK8F7580
Dactinomicina
DACTINOMYCIN
Dactinomycin [USAN:USP:INN:BAN]
Dactinomycin, United States Pharmacopeia (USP) Reference Standard
Dactinomycine
Dactinomycinum
DB00970
Dilactone actinomycindioic D acid
DSSTox_CID_31
DSSTox_GSID_20031
DSSTox_RID_75330
DTXSID9020031
DVA-DPR-SAR-MVA-(c1)DTH-PXZ-(c11)DTH-DVA-DPR-SAR-MVA
EINECS 200-063-6
FT-0080366
Glycopeptide, 4a
GNF-Pf-2290
HMS2052O17
Lyovac-Cosmegen
Meractinomycin
MFCD00005033
MLS001424196
MolPort-003-925-177
NC00384
NCGC00090796-01
NCGC00161622-01
NCGC00161622-02
NCGC00260031-01
NCGC00271789-02
NCI-C04682
NSC 3053
NSC3053
PXZ-THR-DVA-PRO-SAR-MVA-THR-DVA-PRO-SAR-MVA
RJURFGZVJUQBHK-IIXSONLDSA-N
SAM001246846
SCHEMBL3844
SMR000469227
Specific stereoisomer of N,N'-((2-amino-4,6-dimethyl-3-oxo-3H-phenoxazine-1,9-diyl)-bis(carbonylimino(2-hydroxypropylidene)carbonyliminoisobutylidenecarbonyl-1,2-pyrrolidinediylcarbonyl(methylimino)methylenecarbonyl))bis(N-me
Stereoisomer of N,N'-((2-amino-4,6-dimethyl-3-oxo-3H-phenoxazine-1,9-diyl)bis(carbonylimino(2-(1-hydroxyethyl)-1-oxo-2,1-ethanediyl)imino(2-(1-methylethyl)-1-oxo-2,1-ethanediyl)-1,2-pyrrolidinediylcarbonyl(methylimino) (1-oxo
Tox21_111997
Tox21_111997_1
Tox21_202482
UNII-0OCC969V50 component RJURFGZVJUQBHK-IIXSONLDSA-N
UNII-1CC1JFE158
UPCMLD-DP055
UPCMLD-DP055:001
UPCMLD-DP055:002

US Patents and Regulatory Information for COSMEGEN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Recordati Rare COSMEGEN dactinomycin INJECTABLE;INJECTION 050682-001 Approved Prior to Jan 1, 1982 AP RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

see a sample report or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
Merck
Deloitte
Chinese Patent Office
Citi
McKesson
UBS
Accenture
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.